reading pharmacology threads from 2024 and half of it aged badly
reading pharmacology threads from 2024 and half of it aged badly — a position I have arrived at slowly and would like tested.
The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary.
Started reading limitations sections first. It has changed how much weight I give to almost everything posted here.
Went looking for human data on a mechanism everybody here asserts. Found preclinical work and one small study. That was clarifying.
Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.
best — the order this archive was captured in
GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.
Push back: a receptor being expressed in a tissue does not tell you the agonist reaches it at therapeutic exposure.
Not convinced by the linearity assumption. Dose-response in this class is not linear and the trials show it.
Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.
preclinical is not clinical and rodents are not small people
albumin binding is most of the half-life story
read the discussion section, that is where the honesty lives
mechanism explains a direction, not a magnitude
the peripheral and central stories are not in competition
Careful — you have a plausible mechanism and no evidence that it is the operative one in the case you are describing.
Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since.
Asked for a citation rather than removing. On this board a claim without one is an invitation, not an offence.
That study was in a rodent model. Worth stating, since the thread has been reading it as human data.
Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.
Right — mechanism gives you a direction. It never gives you an effect size and people use it as though it does.
Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.
the central appetite effect is doing more work than the gut effect
Is that from a human study or a preclinical model?
- 1GLP-1 receptor agonism acts both peripherally — insulin secretion in a…9 comments in this branch · started by u/georgi_chowdhury